Atlas Trials

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Clinical trial NCT06812325 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06812325
Sponsor
Viridian Therapeutics, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Thyroid Eye Disease (TED)
Start date
2025-02-03
Primary completion
2026-04-22
Enrollment
320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.